Potential contributors to efficacy in MCL include disruption of BCR‐dependent survival signaling through direct cytolysis, robust CAR T‐cell expansion within lymphoid and blood compartments where MCL typically resides, and possible immunomodulatory effects of prior BTK inhibition, which may enhance CAR T‐cell function in some patients. This evidence concerns the gene BTK and mantle cell lymphoma.